StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clockwork.io Launches The Industry's First Contractual Commitment to End GPU Waste in AI Training1.7.2026 17:00:00 CEST | Press release
"You Only Compute Once" (YOCO) guarantees to resolve 90% of AI training failures with no lost progress, or customers get credit PALO ALTO, CA / ACCESS Newswire / July 1, 2026 / Clockwork.io, pioneer of Software-Driven AI Fabrics™ and the company behind TorchPass AI fault tolerance, today announced the YOCO Guarantee - the industry's first contractual commitment to dramatically reduce the hidden, compounding cost of training failure in large-scale AI infrastructure. The announcement marks a turning point in how the AI industry measures infrastructure reliability - moving beyond uptime metrics designed for a previous era towards goals AI teams value most: whether the job finishes on time, without losing work. Under the YOCO (You Only Compute Once) Guarantee, Clockwork.io commits that at least 90% of training failures on supported TorchPass workloads will be resolved through live GPU migration, with no lost training progress, no checkpoint rollback, and no recompute. If Clockwork.io falls
Hydrosat Launches Data Discovery Platform, Unlocking 500 Million sq km of Satellite Imagery1.7.2026 15:00:00 CEST | Press release
New portal provides on-demand thermal imagery for critical resource monitoring, risk detection, and operational decision-making worldwide. WASHINGTON, D.C. AND LUXEMBOURG CITY, LUXEMBOURG / ACCESS Newswire / July 1, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced the launch of its new Discovery Portal, a centralized gateway for customers to access, explore, and leverage thermal imagery and analytics from space. The Discovery Portal enables organizations to access and evaluate thermal intelligence products powered by Hydrosat's flagship 30 m pixel-size Land Surface Temperature data set and growing constellation of thermal infrared satellites. Unlike traditional optical imagery, thermal imagery captures heat signatures from the Earth's surface, providing actionable insights across vast geographic areas, day or night, and often in conditions where conventional imaging is limited. With over 500 million sq km of imagery alre
Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202630.6.2026 20:55:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 30, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2026, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2026 of $35,855,341 Total cash as at April 30, 2026 of $664,328 Working capital deficiency as at April 30, 2026 of $2,683,766 Shareholder's equity as at April 30, 2026 of $32,258,687 During the three-month period ended April 30, 2026, the Company incurred $57,783 in cost for exploration activities at the TBN project. During the quarter, the Company has been pursuing project financing alternatives while continuing to advance critical aspects of the project including progressing Advanced Exploration permitting discussions, and detailed planning for the next phase of exploration at E
Sauce Labs Becomes the First Dedicated Software Quality Platform to Achieve ISO 42001 Certification for Responsible AI30.6.2026 17:00:00 CEST | Press release
As AI takes on decisions that used to belong to engineers, the world's largest continuous testing cloud joins the small group of companies in any industry independently certified to govern AI responsibly SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2026 / Sauce Labs, the world's largest continuous testing cloud, today announced it has achieved ISO/IEC 42001 certification, the first international standard for the responsible management of artificial intelligence. The certification covers Sauce AI, including Sauce AI for Insights and Sauce AI for Test Authoring, and makes Sauce Labs the first company dedicated to software quality to bring its AI capabilities under a fully certified AI Management System. Only a small number of companies worldwide, in any industry, have cleared this bar. Software is being written faster than at any point in history, and AI is now making quality decisions that used to belong to engineers. That shift has changed the question enterprise buyers ask. It is no
Human-Robot Collaboration Takes Center Stage at Prestigious Logistics Award30.6.2026 15:00:00 CEST | Press release
Denmark's The Mobile Robot Company wins IFOY Industrial Truck of the Year 2026 with a self-driving pallet jack built to empower warehouse operators rather than replace them. STUTTGART, DE / ACCESS Newswire / June 30, 2026 / In warehouses and factories, much of the work that keeps goods moving is still measured in footsteps. Operators walk the same routes, push the same loads, and repeat the same transport tasks hour after hour. For years, automation has promised to remove that work, but often with a catch: complex projects, fixed infrastructure, long integrations, and systems that assume people should be designed out of the process. At this year's IFOY AWARD, one of intralogistics' most respected technology prizes, the Industrial Truck of the Year award went to a different idea. The Mobile Robot Company, a young Danish robotics startup, won the 2026 title for the J1600 self-driving pallet jack, a robot designed not to replace the warehouse operator, but to work under the operator's dir
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom